Avdoralimab  (Synonyms: IPH 5401; Anti-C5aR1 mAb)

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research^[1].

Avdoralimab (IPH 5401) selectively blocks the C5a-C5aR1 interaction and its downstream signaling in human myeloid cells. In vitro, C5aR1 blockade with Avdoralimab (10-30 μg/mL) inhibits C5a-induced neutrophil activation. Avdoralimab blocks the neutrophil activation induced by very high concentrations of C5a. Avdoralimab also inhibits the C5a-induced migration of neutrophils in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In mice with a knock in for human C5aR1 (HuC5aR1 KI mice), Avdoralimab blocks the infiltration of neutrophils and monocytes, prevents albumin release in broncho-alveolar lavage fluid (BALF) and limits C5a-induced acute lung injury (ALI) histopathological features^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2226393-85-5

Liquid

Colorless to light yellow

[Avdoralimab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150.  [Content Brief]